<DOC>
	<DOCNO>NCT01543672</DOCNO>
	<brief_summary>Treatment large tumor volume ≥ 2 lung metastasis simultaneously lung cancer patient use Stereotactic Body Radiation Therapy ( SBRT ) mean-lung dose escalation study .</brief_summary>
	<brief_title>Irradiation Large Lung Tumors Two More Lung Metastases Simultaneously</brief_title>
	<detailed_description>A phase I/II multicenter trial conduct patient medically inoperable peripheral non small cell lung cancer ( NSCLC ) &gt; 5 cm without lymph node involvement ( group A ) medically ≥ 2 lung metastasis ( group B ) . Radiation pneumonitis expect dose-limiting patient evidence incidence predict mean lung dose ( MLD ) . The MLD escalation perform separately patient group , use time-to-event continual reassessment method ( TITE-CRM ) . All patient receive 3-5 fraction SBRT lung tumor ( ) , minimum mean PTV dose ≥ 42 Gy . Fraction size may downscaled base MLD constraint .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Inclusion Criteria group A B : Weight loss &lt; 10 % last three month . WHOperformance status ≤ 2 Medical inoperable patient patient refuse surgery . Chemotherapy allow neoadjuvant adjuvant setting , exclusion period 4 week preSBRT 6 week postSBRT . Before patient registration , write informed consent must give accord ICH/GCP , national local regulation . Risk group A specification : NSCLC ( Cytological histological proven ) patient peripheral tumor &gt; 5 cm tumor stag cT2bN0M0 cT3N0M0 ( chest wall infiltration exclusion criterion , long tumor diameter &gt; 5 cm ) . Single peripheral lung metastasis inoperable patient diameter &gt; 5 cm . In case first presentation metastatic disease , cytological histological proof obligate . In patient without cytological histological confirmation NSCLC , grow FDGPET positive lesion ( SUV &gt; 5 ) accept contraindication invasive diagnostic examination ( refusal ) present . Risk group B specification : Patients ≥ 2 simultaneous peripheral lung metastasis ≤ 5 cm origin location lung . In case first presentation metastatic disease , cytological histological proof obligate . This necessary case history already proven disseminated disease . Patients ≥ 2 peripheral lung metastasis without unacceptable dose overlap . Patients central tumor Pancoast tumor Prior radiotherapy treatment thorax Patients receive systemic treatment SBRT Pregnant patient Patients previously treat adriamycin agent case heart involvement within treatment field .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>lung</keyword>
	<keyword>SBRT</keyword>
	<keyword>MLD</keyword>
	<keyword>toxicity</keyword>
</DOC>